#

Biotechnology

: 158
Aardvark plans to agree on a new phase III trial design with the FDA and resume clinical development of ARD-101 next year / Photo: Unsplash / Julia Koblitz
Small Caps·
Aardvark sinks 65% on data from halted trial of hunger drug; FDA to allow new tests
Merck will acquire Silence Therapeutics, which is developing a treatment for a rare blood cancer / Photo: www.silence-therapeutics.com
Small Caps·
Small caps last week: Deals for Silence and Braze, hair-loss pill success
Regulators have agreed to review Biohaven’s application for approval of an experimental treatment for a rare disease that causes a gradual loss of muscle control / Photo: Facebook / Biohaven
Small Caps·
Biohaven soars 25% as drug moves closer to approval. Is there more upside?
Lycia shares will trade on the Nasdaq under the ticker LYCA / Photo: X / Lycia Therapeutics
Small Caps·
Lycia IPO: Food allergy biotech cofounded by Nobel laureate debuts on the Nasdaq
Life sciences companies stand to gain from a surge in AI fueled drug discovery, says Citrini Research / Photo: Alohaflaminggo / Shutterstock.com
Small Caps·
+1
·
Citrini bets on biotech after using Anthropic AI to design potential drug
Veradermics’ drug could become the first FDA-approved nonhormonal pill for male pattern hair loss, which affects around 50 mln men in the U.S. / Photo: Studio Romantic / Shutterstock
Small Caps·
Veradermics jumps on successful trial of its hair-loss pill. Is the stock a buy?
Disc stock jumped 39% after a successful trial for its drug bitopertin, its best day since late 2022 / Photo: www.discmedicine.com
Small Caps·
Disc Medicine has best day in 4 years as its blood-disorder drug succeeds in trial
The deal comes after Silence Therapeutics reported positive results for its experimental blood cancer medicine / Photo: Kittyfly / Shutterstock
Small Caps·
Silence Therapeutics soars 125% as Merck to acquire developer of blood cancer drug
The Russell 2000 entered a technical correction on Wednesday for the first time since March / Photo: Facebook / NYSE
Small Caps·
Small caps last week: Russell 2000 correction, Bumble sale, Crocs celeb partnerships
The company is developing RNAi-based drugs to treat thromboembolic diseases and Stargardt disease, with its lead product in early-stage trials / Photo: City Therapeutics
Small Caps·
City Therapeutics IPO: Developer of RNAi-based drugs debuts on the Nasdaq
Data on the subcutaneous form of Skyrizi likely drove the rise in AbbVies stock / Photo: ChrisStock82 / Shutterstock.com
News·
Pharmaceutical companies benefited from the sell-off in the AI sector. Which stocks are nearing their all-time highs?
Iambic develops cancer drugs using its AI platform / Photo: Iambic
Small Caps·
Iambic IPO: Biotech backed by Nvidia and Cathie Wood debuts on the Nasdaq
Load more